Ionis Pharmaceuticals
IONS
308 hedge funds and large institutions have $4.93B invested in Ionis Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 111 increasing their positions, 94 reducing their positions, and 48 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 111 | Existing positions reduced: 94
2.43% more ownership
Funds ownership: 91.83% → 94.26% (+2.4%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
3% less capital invested
Capital invested by funds: $5.07B → $4.93B (-$144M)
6% less funds holding
Funds holding: 326 → 308 (-18)
21% less call options, than puts
Call options by funds: $45.1M | Put options by funds: $56.9M
35% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 48
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$134M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$25.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$24.7M |
| 4 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$20M |
| 5 |
PCM
Peregrine Capital Management
Minneapolis,
Minnesota
|
+$14.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$31.3M |
| 2 |
Two Sigma Investments
New York
|
-$15.8M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
-$13.8M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$13.1M |
| 5 |
Goldman Sachs
New York
|
-$12.9M |
IONS Hedge Fund Activity: Q2 2018 in Review
308 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q2 2018, worth a combined $4.93B — down 2.8% from $5.07B a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of IONS and 31 opened new positions — a net loss of 17 holders — while 94 trimmed existing stakes and 111 added.
The largest buyer was Baillie Gifford & Co, adding an estimated $134M. The largest seller was Wellington Management Group, cutting an estimated $31.3M.
- 308 institutional investors held Ionis Pharmaceuticals (IONS) as of Q2 2018, down from 326 in Q1 2018.
- Funds reported $4.93B of Ionis Pharmaceuticals stock for Q2 2018, down 2.8% quarter-over-quarter.
- 31 funds opened new Ionis Pharmaceuticals positions in Q2 2018 and 48 closed out, a net change of -17 holders.
- The largest Ionis Pharmaceuticals buyer in Q2 2018 was Baillie Gifford & Co, an estimated $134M added.
- The largest Ionis Pharmaceuticals seller in Q2 2018 was Wellington Management Group, an estimated $31.3M sold.
Based on aggregated 13F filings for Q2 2018.